MedTrace Logo

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

NCT03862846 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-07-16

No results posted yet for this study

Summary

The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy

Conditions

  • Primary Mitochondrial Myopathy

Interventions

DRUG

REN001

Once daily

Sponsors & Collaborators

  • Reneo Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Grainne Gorman, MD · Wellcome Centre for Mitochondrial Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-10
Primary Completion
2020-04-23
Completion
2020-04-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03862846 on ClinicalTrials.gov